Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma*
暂无分享,去创建一个
Yiling Lu | Emanuel F. Petricoin | Virginia Espina | Elaine W. Kay | Gordon B. Mills | David Fishman | Lance A. Liotta | E. Petricoin | G. Mills | L. Liotta | Yiling Lu | R. Araujo | V. Espina | D. Fishman | J. Wulfkuhle | R. Speer | E. Kay | V. Calvert | Joy Aquino | K. Sheehan | Katherine M. Sheehan | Valerie S. Calvert | Joy Aquino | Runa Speer | Robyn Araujo | Julia D. Wulfkuhle
[1] S. Nock,et al. Recent developments in protein microarray technology. , 2003, Angewandte Chemie.
[2] E. Petricoin,et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays , 2003, Proteomics.
[3] Emanuel F Petricoin,et al. Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.
[4] Y. Yatabe,et al. Phenotypic composition of salivary gland tumors: an application of principle component analysis to tissue microarray data , 2004, Modern Pathology.
[5] M. Snyder,et al. Protein arrays and microarrays. , 2001, Current opinion in chemical biology.
[6] Virginia Espina,et al. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. , 2004, Journal of proteome research.
[7] L. Weber. Multi-component reactions and evolutionary chemistry. , 2002, Drug discovery today.
[8] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[9] L. Liotta,et al. Use of proteomic analysis to monitor responses to biological therapies , 2004, Expert opinion on biological therapy.
[10] Pascal Furet,et al. Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.
[11] E. Petricoin,et al. Clinical proteomics: personalized molecular medicine. , 2001, JAMA.
[12] Robert C. Bast,et al. Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.
[13] Emanuel F. Petricoin,et al. Network-targeted combination therapy : a new concept in cancer treatment , 2004 .
[14] Mauro Ferrari,et al. Opportunities for Nanotechnology-Based Innovation in Tissue Proteomics , 2004, Biomedical microdevices.
[15] Illinois.,et al. Cancer Genetics , 1976, British Journal of Cancer.
[16] S. Langdon,et al. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’) , 2002, British Journal of Cancer.
[17] Masahiro Fukuoka,et al. Gefitinib — a novel targeted approach to treating cancer , 2004, Nature Reviews Cancer.
[18] J. Kavanagh,et al. Novel Agents in Epithelial Ovarian Cancer , 2004, Cancer investigation.
[19] Emanuel F Petricoin,et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays , 2003, Proteomics.
[20] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[21] R. McPherson,et al. The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[22] M. Campiglio,et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] E. Petricoin,et al. Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy , 2004, Human Genomics.
[24] A. Ullrich,et al. Receptor tyrosine kinases as targets for anticancer drugs. , 2002, Trends in molecular medicine.
[25] R P Araujo,et al. A mathematical model of combination therapy using the EGFR signaling network. , 2005, Bio Systems.
[26] William C Reinhold,et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[27] Larry Gold,et al. Dimensionality is the issue: use of photoaptamers in protein microarrays. , 2002, Current opinion in biotechnology.
[28] John Quackenbush,et al. Universal RNA reference materials for gene expression. , 2004, Clinical chemistry.
[29] S R Gullans,et al. DNA microarray analysis of complex biologic processes. , 2001, Journal of the American Society of Nephrology : JASN.
[30] M. Raspollini,et al. c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] H. Hug,et al. Advances in recombinant antibody microarrays. , 2004, Clinica chimica acta; international journal of clinical chemistry.
[32] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[33] Emanuel Petricoin,et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray , 2004, Laboratory Investigation.
[34] L. Tan,et al. Her-2/neu and breast cancer. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[35] S. Hanash,et al. Disease proteomics , 2003, Nature.
[36] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[37] Napoleone Ferrara,et al. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.
[38] D. Metcalfe,et al. The biology of Kit in disease and the application of pharmacogenetics. , 2004, The Journal of allergy and clinical immunology.
[39] Thomas Joos,et al. Protein microarray technology , 2004, Expert review of proteomics.
[40] D. Bodurka,et al. Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epithelium , 2003, Cancer.
[41] H. Ge,et al. UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. , 2000, Nucleic acids research.
[42] M. Tyers,et al. From genomics to proteomics , 2003, Nature.
[43] Stephen S. Taylor,et al. Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.
[44] L. Liotta,et al. Proteomic profiling of the cancer microenvironment by antibody arrays , 2001, Proteomics.
[45] Gavin MacBeath,et al. Protein microarrays and proteomics , 2002, Nature Genetics.
[46] S. Schreiber,et al. Printing proteins as microarrays for high-throughput function determination. , 2000, Science.
[47] J. Sebolt-Leopold. Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.
[48] J. She,et al. Protein microarrays to detect protein-protein interactions using red and green fluorescent proteins. , 2002, Analytical biochemistry.
[49] F. Pontén,et al. Affinity Proteomics for Systematic Protein Profiling of Chromosome 21 Gene Products in Human Tissues* , 2003, Molecular & Cellular Proteomics.
[50] T. Barrette,et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. , 2001, Cancer research.
[51] E. B. Butler,et al. Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers , 2003, Proteomics.
[52] Virginia Espina,et al. Protein microarrays: Molecular profiling technologies for clinical specimens , 2003, Proteomics.
[53] Vince R. Boveia,et al. Development of multiplexed protein profiling and detection using near infrared detection of reverse-phase protein microarrays , 2004, Clinical Proteomics.
[54] J. Baselga,et al. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] E. Petricoin,et al. Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.
[56] E. Petricoin,et al. Laser Capture Microdissection , 1996, Science.
[57] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[58] M. Snyder,et al. Protein chip technology. , 2003, Current opinion in chemical biology.
[59] D. Bray. Molecular Networks: The Top-Down View , 2003, Science.
[60] J F Lawless,et al. Regression and recursive partition strategies in the analysis of medical survival data. , 1988, Journal of clinical epidemiology.
[61] T. Hunter,et al. Signaling—2000 and Beyond , 2000, Cell.
[62] R. Christopherson,et al. Antibody arrays: an embryonic but rapidly growing technology. , 2002, Drug discovery today.
[63] R. Scolyer,et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors , 2004, Modern Pathology.
[64] J. Ioannidis,et al. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment , 2003, The Lancet.
[65] R. Albert,et al. The large-scale organization of metabolic networks , 2000, Nature.
[66] William C Reinhold,et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. , 2003, Cancer research.
[67] P. Guldberg,et al. Towards discovery‐driven translational research in breast cancer , 2004, The FEBS journal.
[68] G. Evan,et al. Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.
[69] P. Cutler. Protein arrays: The current state‐of‐the‐art , 2003, Proteomics.
[70] B. Leyland-Jones. Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.
[71] E. Eisenhauer,et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] Emanuel F Petricoin,et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. , 2002, Briefings in functional genomics & proteomics.
[73] Emanuel F Petricoin,et al. Protein microarray detection strategies: focus on direct detection technologies. , 2004, Journal of immunological methods.
[74] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[75] E. Partridge,et al. Epithelial ovarian cancer: Prevention, diagnosis, and treatment , 1999, CA: a cancer journal for clinicians.
[76] J. Celis,et al. Proteomics in translational cancer research: toward an integrated approach. , 2003, Cancer cell.
[77] R. Salgia,et al. Targeting c-Kit mutations: basic science to novel therapies. , 2004, Leukemia research.
[78] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.